Global Immunology Treatment Market Will Exceed $74 Billion by 2022; Finds New Report

Despite the imminent patent expiry of many therapies, the global immunology treatment market is set to expand, from $61.5 billion in 2015 to reach $74.2 billion in 2022, according to new research.

According to the company’s latest report, the immunology treatment market’s Compound Annual Growth Rate (CAGR) will equal a relatively stable 2.71%, due to practical and regulatory barriers to entry for biosimilars that are not present for small molecule generics, and a moderately strong late-stage pipeline.

According to Senior Analyst, says: “This market is a lucrative area as up to 7% of western populations are thought to be affected by chronic immunological disorders. Consequently, the pharmaceutical pipeline for immunology is considerable, with 1,896 products currently in active development.

“While 85 of these are in Phase III of the process, it must be acknowledged that 73% of these pipeline products are in early developmental stages.”

Publisher’s study suggests there are a number of prospective products expected to achieve strong annual revenues during the forecast period, although these are not anticipated to achieve revenues comparable to those generated by the current strongest-selling immunology products.

Senior Analyst explains: “To date, the most clinically and commercially effective drugs have been in a class of compounds known as monoclonal Antibodies (mAbs), which includes blockbuster products such as Humira (adalimumab) and Remicade (infliximab).

“APB-501, a biosimilar of Humira, which was the best-selling drug of 2014 worldwide, is anticipated to generate annual revenues of almost $1 billion by 2022, making it an exceptionally strong-performing non-patented drug.”

The analyst adds that while the immunology therapeutics market is a very commercially active area, with a number of exceptionally high-selling products present, revenues for these key drugs are expected to undergo a steady decline towards the end of the period.

Senior Analyst concludes: “Publisher believes that revenues for immunology therapeutics will only significantly decline in the long term, beyond the forecast period. This is due to the protective effect of the practical and regulatory challenges in fielding biosimilar products, which reduces the impact of patent expiries on biologics, compared with small molecules.”

Global Immunology Market to 2022 - Large pipeline and competitive market to drive long-term market growth report provides analysis of the immune-mediated inflammatory diseases treatment pipeline, stratified by stage of development, molecule type and molecular target. It includes information on the current clinical and commercial landscape, and the composition of the immunology therapeutics space in terms of dominant molecule types and targets, as well as highlighting key market players and their future prospects.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by Publisher’s team of industry experts.

For more information Visit at: http://mrr.cm/oVr

Find all Therapeutic Report at: http://www.marketresearchreports.com/therapeutic

Chronic Obstructive Pulmonary Disease Treatment Pipeline Lacks Robust Innovation; According to New Research

Despite an influx of new therapies over recent years, the Chronic Obstructive Pulmonary Disease (COPD) treatment market has a number of unmet needs, and the innovation in its product development pipeline is lagging in comparison to other indications, According to Research.

According to the company’s latest report, while currently-available drugs aim to manage the symptoms associated with COPD by reducing the frequency and severity of exacerbations and improving lung function, none have been shown to modify long-term disease progression.

According to Senior Analyst, states that in addition to the need for disease-modifying drugs, much of the unmet need associated with COPD has been linked to poor adherence to medication.

Senior Analyst says: “Tedious drug delivery processes and the need for frequent daily doses ultimately lead to poor compliance and management of COPD symptoms. As a consequence, drug development programs are focusing on long-acting medication.

“There is also a need for alternative anti-inflammatory agents. Traditionally reliant on Inhaled Corticosteroids (ICS), analysis of the COPD product development pipeline has confirmed greater interest into novel anti-inflammatory agents.”

The analyst adds that beyond ICS therapy, the current market offers very limited anti-inflammatory treatment, which is a notable unmet need in COPD.

The report also states that first-in-class product development in COPD treatment constitutes only 16.5% of the pipeline, which is relatively small compared to other respiratory indications. For example, asthma therapeutics exhibit greater innovation, with first-in-class products making up 23% of the pipeline.

Senior Analyst continues: “There are suggestions that such innovation is filtering through into the COPD therapeutics pipeline, as asthma and COPD share mechanisms of pathophysiology, making it likely that products will be applicable to both diseases.

“In this way, innovations in the asthma treatment pipeline will significantly aid that of COPD. However, there is no clear indication that disease-modifying drugs will be released onto the COPD market any time soon, making it an attractive proposition for major pharma players.”

Frontier Pharma: Chronic Obstructive Pulmonary Disease (COPD) - Identifying and Commercializing First-in-Class Innovation report provides analysis of the Chronic Obstructive Pulmonary Disease (COPD) treatment pipeline, stratified by stage of development, molecule type and molecular target. It includes information on the current clinical and commercial landscape, and the composition of the COPD therapeutics market in terms of dominant molecule types and targets, as well as highlighting current unmet needs.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by Publisher’s team of industry experts.

For more information Visit at: http://mrr.cm/oVH

Find all Diseases Report at: http://www.marketresearchreports.com/diseases

Global Breast Cancer Treatment Market Will Reach $17.2 Billion by 2021; Finds New Report

The global breast cancer therapeutics market is set to increase in value from $10.4 billion in 2014 to $17.2 billion by 2021, at a Compound Annual Growth Rate (CAGR) of 7.3%, according to new research.

The company’s latest report states that this strong growth will be primarily due to substantial increases in the prevalence of breast cancer, with rates of the disease expected to rise over the forecast period due to an aging population, changing lifestyles and higher survival rates.

According to Senior Analyst, says that the introduction of several new therapies will help to drive breast cancer treatment market growth by 2021.

Senior Analyst explains: “In terms of upcoming breast cancer treatments, the overall pipeline is strong, with 743 products, and the early pipeline has many experimental molecules designed to target novel pathways.

“Promising pipeline drugs include abemaciclib, buparlisib, LEE 011, Olaparib and NeuVax, all of which are expected to be approved within the forecast period and have demonstrated significant clinical benefits in trials. In addition, rapid uptake of premium-priced biologics, such as Perjeta and Kadcyla, in all settings of the disease will contribute to the market growth.”

Despite this, the analyst notes that the late-stage breast cancer pipeline is weak, with only 6% of candidates in Phase III of development, and targeted therapies, currently unrepresented by marketed products, almost non-existent within this phase.

The report also states that the market will face some limitations due to patent expirations creating substantial opportunity for generic and biosimilar manufacturers.

Senior Analyst continues: “The patents for a number of key breast cancer drugs, including Afinitor, Avastin and Herceptin, are expected to expire during the forecast period. However, the use of combinations of branded therapies in both the early-stage and metastatic settings will increase the Annual Cost of Therapy (ACoT) and offset the impact of patent expiries.

“For example, the ACoT for the combination of Perjeta with Herceptin is three times that of Herceptin monotherapy in both adjuvant and metastatic settings in the US. Therefore, even though Herceptin is set to expire in the near future, this will be offset by the approval of newer combination therapies and the growth of current premium therapies.”

Breast Cancer Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rapid Uptake of Premium Priced Biologics and Rising Incidence report provides analysis of the breast cancer treatment pipeline, stratified by stage of development, molecule type and mechanism of action. It includes information on the current clinical and commercial landscape, unmet needs, and annualized market data from 2014 and forecast to 2021.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by Publisher’s team of industry experts.

For more information Visit at: http://mrr.cm/oVV

Find all Therapeutic Report at: http://www.marketresearchreports.com/therapeutic

Global Endoscopy Market Value Will Climb to Almost $9.7 Billion by 2021; Finds New Report

The global endoscopy market will rise in value from $5.7 billion in 2014 to just under $9.7 billion by 2021, representing a Compound Annual Growth Rate (CAGR) of 6.9%, according to new research.

The company’s latest report states that this growth, which will occur across the 10 major markets of the US, France, Germany, Italy, Spain, UK, Japan, Brazil, China and India, will be driven primarily by increasing adoption of endoscopic surgeries and screening programs, as well as a rising patient population.

According to Senior Analyst covering Medical Devices, says the use of minimally invasive endoscopy techniques for both diagnostic and therapeutic purposes will increase in proportion with the rising prevalence of diseases worldwide.

Senior Analyst explains: “Endoscopy offers the possibility of accurate visualization of the current state of patients with a variety of diseases, which consequently improves the treatment process. Early disease diagnosis is the key to reducing healthcare expenses, meaning endoscopy techniques play a vital role in treating patients in the most cost-effective manner.

The most promising areas of growth are colonoscopy, gastroscopy, cystoscopy, bronchoscopy, laryngoscopy, and endoscopy visualization systems, where there has been significant focus in terms of pipeline development.

The report also states that the endoscopy market is highly fragmented and experiences fierce pricing competition, meaning companies require shrewd corporate strategies in order to increase their market shares.

Senior Analyst continues: “In the US market, Olympus holds the number one spot, with the top five players commanding 80% of the market. Olympus’ closest competitor is Karl Storz, which has a particularly strong product portfolio in the endourology space.

“The remaining 20% of the US endoscopy market is occupied by the small-to-medium enterprises that are involved in cutting-edge research. One such upcoming company is EndoChoice with its innovative Fuse GI endoscopy system.”

According to Publisher, the US had the leading share of the endoscopy market with 45.8% in 2014, and this is forecast to increase to 48.8% by 2021, by which time it will contribute revenues of just over $4.7 billion.

MediPoint: Endoscopy - Global Analysis and Market Forecasts report provides analysis of the endoscopy space across the 10 major markets of the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, China and India, including annualized market data from 2014 and forecast until 2021.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by Publisher’s team of industry experts.

Find more information Visit at: http://mrr.cm/oVR

Find all Diseases Report at: http://www.marketresearchreports.com/diseases